title: SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory.
abstract: SALTIRE and RAAVE were the first two studies to evaluate the use of statin therapy for impeding calcific aortic valve disease (CAVD). This review presents the findings of low-density lipoprotein (LDL)-density-radius theory as tested using the combined results from the SALTIRE and RAAVE studies. Patients who received statin therapy had a greater degree of LDL cholesterol lowering, seen as the % change in LDL (47 vs 2%, p = 0.012), which in itself was significantly associated with a lesser change in aortic valve area (AVA; p < 0.001 and R(2) = 0.27). The percent change in the AVA for the treated patients was 5% and 15% for the nontreated patients (p = 0.579 and R(2) = 0.03). In summary, these published findings suggest that when applying the LDL-density-radius theory, which combines the cellular biology and the hemodynamics as defined by the continuity equation for AVA, there may be a role for lipid-lowering therapy in contemporary patients with calcific aortic valve disease (CAVD).
authors: Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
authors: Nalini M
authors: NM
authors: Rajamannan
authors: Anders M
authors: AM
authors: Greve
authors: Luis M
authors: LM
authors: Moura
authors: Patricia
authors: P
authors: Best
authors: Kristian
authors: K
authors: Wachtell
mesh_terms: D001021:Aortic Valve / Q000473:pathology*; D001024:Aortic Valve Stenosis / Q000097:blood / Q000188:drug therapy*; D002114:Calcinosis / Q000097:blood / Q000188:drug therapy*; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: aortic valve stenosis; atherosclerosis; calcification; clinical trials; hemodynamics; statins